We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

433 hedge funds and large institutions have $18.6B invested in Alnylam Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 157 increasing their positions, 131 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 40

32% more call options, than puts

Call options by funds: $249M | Put options by funds: $189M

20% more repeat investments, than reductions

Existing positions increased: 157 | Existing positions reduced: 131

7% more funds holding

Funds holding: 403 → 433 (+30)

0.24% less ownership

Funds ownership: 93.95% → 93.7% (-0.24%)

11% less capital invested

Capital invested by funds: $21B → $18.6B (-$2.35B)

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
433
Holders Change
+30
Holders Change %
+7.44%
% of All Funds
6.66%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.11%
New
76
Increased
157
Reduced
131
Closed
40
Calls
$249M
Puts
$189M
Net Calls
+$59.8M
Net Calls Change
-$76.6M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
JP Morgan Chase
JP Morgan Chase
New York
+$97.8M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$89.2M
4
FCM
Farallon Capital Management
California
+$69.8M
5
RI
RTW Investments
New York
+$54.4M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$232M
2
Morgan Stanley
Morgan Stanley
New York
-$152M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$97.9M
4
Alkeon Capital Management
Alkeon Capital Management
New York
-$73.7M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$44.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
376
Atlas Capital Advisors
Wyoming
$28K – – –
GWS
377
Glassman Wealth Services
Virginia
$25K +$2.42K +13 +9%
GTAM
378
Global Trust Asset Management
Florida
$21K -$2.42K -13 -10%
TFM
379
TFC Financial Management
Massachusetts
$21K – – –
Optiver Holding
380
Optiver Holding
Netherlands
$21K +$23K +124 New
CWP
381
Concord Wealth Partners
Virginia
$20K +$7.06K +38 +47%
GI
382
Gradient Investments
Minnesota
$19K – – –
LWP
383
Lumature Wealth Partners
Georgia
$17K -$9.29K -50 -33%
SOW
384
State of Wyoming
Wyoming
$16K -$8.73K -47 -33%
HNB
385
Huntington National Bank
Ohio
$14K -$929 -5 -6%
CFGS
386
Concourse Financial Group Securities
Alabama
$12K +$5.58K +30 +71%
CTC
387
Central Trust Company
Missouri
$11K – – –
EARNEST Partners
388
EARNEST Partners
Georgia
$10K – – –
FHA
389
First Horizon Advisors
Tennessee
$10K +$2.42K +13 +23%
C
390
Covestor
United Kingdom
$10K +$10.4K +56 New
AF
391
Allworth Financial
California
$10K +$11.3K +61 New
DFCM
392
Dark Forest Capital Management
Puerto Rico
$9K +$10.2K +55 New
MFAM
393
Motley Fool Asset Management
Virginia
$9K +$10.4K +56 New
PFSC
394
Peoples Financial Services Corp
Pennsylvania
$8K – – –
SJIM
395
St. Johns Investment Management
Florida
$8K – – –
MW
396
Milestone Wealth
New York
$8K +$9.11K +49 New
Robeco Institutional Asset Management
397
Robeco Institutional Asset Management
Netherlands
$7K +$7.25K +39 New
SFO
398
Standard Family Office
South Dakota
$7K +$7.43K +40 New
BWL
399
Bogart Wealth LLC
Virginia
$6K – – –
WT
400
Whittier Trust
California
$6K – – –
14 15
16
17 18

ALNY Hedge Fund Activity: Q4 2021 in Review

433 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2021, worth a combined $18.6B — down 11% from $21B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new ALNY positions and 40 closed out — a net gain of 36 holders — while 157 added to existing stakes and 131 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was BlackRock, cutting an estimated $232M.

  • 433 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2021, up from 403 in Q3 2021.
  • Funds reported $18.6B of Alnylam Pharmaceuticals stock for Q4 2021, down 11% quarter-over-quarter.
  • 76 funds opened new Alnylam Pharmaceuticals positions in Q4 2021 and 40 closed out, a net change of +36 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q4 2021 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Alnylam Pharmaceuticals seller in Q4 2021 was BlackRock, an estimated $232M sold.

Based on aggregated 13F filings for Q4 2021.